Navigation and service

Entrepreneurs Develop Drugs Against Alzheimer’s

New mechanism of action developed

Düsseldorf/Jülich, 22 September 2017 – The development of novel therapies and drugs for the treatment of diseases such as Alzheimer’s is the focus of a spin-off company from Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. “Priavoid GmbH”, the company founded by Prof. Dieter Willbold and his team, took up its work a few days ago. The scientists have developed a candidate drug for the treatment of Alzheimer’s. This drug has now passed the preclinical tests. The scientists have been supported by Forschungszentrum Jülich, the Helmholtz Validation Fund, the university of Düsseldorf, and the Volkswagen Foundation.

More (in German)

Logo

 

 

 

YOUR OPINION MATTERS!

 

Dear visitor,

To make our website suit your needs even more and to give it a more appealing design, we would like you to answer a few short questions.

Answering these questions will take approx. 10 min.

Start now Close window

Thank you for your support!

 

In case you have already taken part in our survey or in case you have no time to take part now, you can simply close the window by clicking "close".

If you have any questions on the survey, please do not hesitate to contact: webumfrage@fz-juelich.de.

 

Your Team at Forschungszentrum Jülich

 

Note: Forschungszentrum Jülich works with the market research institute SKOPOS to anonymously conduct and analyze the survey. SKOPOS complies with the statutory requirements on data protection as well as with the regulations of ADM (Arbeitskreis Deutscher Markt- und Sozialforschungsinstitute e.V.) and ESOMAR (Europäische Gesellschaft für Meinungs- und Marketingforschung). Your data will not be forwarded to third parties.